Article ID Journal Published Year Pages File Type
5599470 Atherosclerosis 2016 9 Pages PDF
Abstract
Alirocumab 300 mg Q4W is a viable additional treatment option in patients requiring LDL-C-lowering.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Preview
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Authors
, , , , , , , , ,